Amylyx Pharmaceuticals, Inc./$AMLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
Ticker
$AMLX
Sector
Primary listing
Employees
123
Headquarters
Website
AMLX Metrics
BasicAdvanced
$1.4B
-
-$2.41
-0.45
-
Price and volume
Market cap
$1.4B
Beta
-0.45
52-week high
$15.15
52-week low
$2.60
Average daily volume
2M
Financial strength
Current ratio
8.723
Quick ratio
8.45
Long term debt to equity
3.155
Total debt to equity
3.551
Profitability
EBITDA (TTM)
-196.297
Gross margin (TTM)
37,961.04%
Net profit margin (TTM)
75,341.37%
Operating margin (TTM)
79,106.43%
Effective tax rate (TTM)
0.34%
Management effectiveness
Return on assets (TTM)
-46.74%
Return on equity (TTM)
-87.42%
Valuation
Price to revenue (TTM)
-4,198.999
Price to book
7.13
Price to tangible book (TTM)
7.13
Price to free cash flow (TTM)
-5.177
Free cash flow yield (TTM)
-19.31%
Free cash flow per share (TTM)
-2.592
Growth
Revenue change (TTM)
-100.08%
Earnings per share change (TTM)
-1.95%
3-year revenue growth (CAGR)
-4.40%
3-year earnings per share growth (CAGR)
-21.41%
Bulls say / Bears say
Amylyx had $180.8 million in cash, cash equivalents, and marketable securities as of June 30, 2025, enough funding to last through the end of 2026 and easing near-term financing concerns (Reuters).
The U.S. FDA granted Fast Track designation to AMX0114, Amylyx’s antisense oligonucleotide targeting calpain-2 for ALS, which allows for more frequent FDA meetings and may enable Priority Review for a faster path to approval (Business Wire).
Long-term, 48-week data from the Phase 2 HELIOS study of AMX0035 in Wolfram syndrome showed sustained improvement or stabilization in pancreatic function, glucose control, vision, and overall clinical status—supporting the move to a Phase 3 trial (BioSpace).
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
AMLX News
AllArticlesVideos
Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock
Business Wire4 weeks ago
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
Business Wire4 weeks ago
Amylyx to stop development of rare brain disorder drug after trial failure
Reuters1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amylyx Pharmaceuticals, Inc. stock?
Amylyx Pharmaceuticals, Inc. (AMLX) has a market cap of $1.4B as of October 04, 2025.
What is the P/E ratio for Amylyx Pharmaceuticals, Inc. stock?
The price to earnings (P/E) ratio for Amylyx Pharmaceuticals, Inc. (AMLX) stock is 0 as of October 04, 2025.
Does Amylyx Pharmaceuticals, Inc. stock pay dividends?
No, Amylyx Pharmaceuticals, Inc. (AMLX) stock does not pay dividends to its shareholders as of October 04, 2025.
When is the next Amylyx Pharmaceuticals, Inc. dividend payment date?
Amylyx Pharmaceuticals, Inc. (AMLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Amylyx Pharmaceuticals, Inc.?
Amylyx Pharmaceuticals, Inc. (AMLX) has a beta rating of -0.45. This means that it has an inverse relation to market volatility.